drugset / Trial / NCT05380024
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
Timeline
- Start
- 2022-08-17
- Primary completion
- 2023-12-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ensartinib | Small molecule | 225 mg | — |